Swedbank AB Has $354.05 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Swedbank AB decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,812,116 shares of the company’s stock after selling 134,161 shares during the period. Swedbank AB owned about 0.40% of Zoetis worth $354,051,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. SageView Advisory Group LLC grew its holdings in shares of Zoetis by 9.1% in the 4th quarter. SageView Advisory Group LLC now owns 5,553 shares of the company’s stock worth $1,063,000 after purchasing an additional 464 shares during the last quarter. ICA Group Wealth Management LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $118,000. MONECO Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $201,000. HighPoint Advisor Group LLC bought a new position in shares of Zoetis in the fourth quarter valued at approximately $1,922,000. Finally, Nomura Holdings Inc. acquired a new position in shares of Zoetis in the 4th quarter worth approximately $1,825,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.2 %

Shares of NYSE:ZTS traded up $0.35 during trading on Tuesday, hitting $193.00. 634,047 shares of the company’s stock traded hands, compared to its average volume of 2,536,315. The company has a 50-day moving average price of $188.43 and a 200-day moving average price of $176.42. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market cap of $88.06 billion, a price-to-earnings ratio of 37.12, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $1.41 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.90%. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.